{"id":"c5e9bbd8-dcb4-4ac8-a830-7913058b5cb9","arxiv_id":"2506.06673","paper_version":1,"verdict":"UNVERDICTED","confidence":"MODERATE","novelty_score":2.0,"correctness_risk":"medium","formal_verification":"none","parameter_count":0,"one_line_summary":"A review of NSUN2 and m5C RNA modification concludes NSUN2 is a promising cancer prognostic and therapeutic target, while contributing only non-significant TCGA survival trends itself.","lead":"This review compiles published evidence that the RNA-modifying enzyme NSUN2 is overexpressed in many cancers and associated with worse patient survival. The authors conclude NSUN2 could be a prognostic marker and drug target, but their only new data, TCGA survival curves, are not statistically significant.","discovery_kind":"review","skeptic_critique":{"model":"deepseek-v4-flash","headline":"Non-significant TCGA survival analyses are presented as corroboration with an unsupported sample-size claim, so the conclusion that NSUN2 is a critical prognostic marker overstates the paper's own evidence.","rationale":"The reader correctly identifies the non-significant survival analyses as the weakest assumption. My stress-test reads the same sections and reaches the same conclusion: the authors' own contribution to the prognostic claim depends on an unsupported extrapolation from null results. This is a real correctness risk because the conclusion states a strong claim ('critical prognostic marker') while the new data in Figs. 4-7 are non-significant and lack methodological detail. I agree with the reader that the broader claim is plausible given the cited literature: several referenced studies report significant associations between high NSUN2 expression and worse survival (e.g., refs. 27, 44, 60, 73-75), and the functional data in cell lines and mouse models support a pro-oncogenic role. Those independent strands give the paper substantial value as a narrative review. However, the paper treats its own non-significant results as corroboration, which is an overstatement. The appropriate remedy is not rejection but conditional acceptance: the authors should remove or clearly relabel the non-significant analyses, provide full methods (cut-off, covariates, HRs), and temper the conclusion to match the title's 'potential prognostic marker.' This would move the reviewer verdict from UNVERDICTED to CONDITIONAL because the requested revisions are concrete and the overall scientific content is otherwise serviceable as a review.","tokens_in":14039,"tokens_out":4345,"duration_ms":46779,"concrete_test":"Re-analyze the four TCGA cohorts (CRC, BLCA, UCEC) with a documented protocol: define high/low NSUN2 by median expression, compute log-rank p-values and Cox hazard ratios with 95% confidence intervals (adjusting for stage and age where available), and perform a power calculation for the observed effect sizes. If the pooled effect is non-significant or the direction is inconsistent across cohorts, or if the sample size required for 80% power is many times larger than the available cohort, the authors' belief is refuted and the non-significant analyses must be labeled inconclusive rather than corroborative.","verdict_should_be":"CONDITIONAL","load_bearing_attack":"Section 2.1.2 (CRC) presents a PFS analysis of 189 TCGA patients (Fig. 4) that is not statistically significant and states: 'We believe that, when the number of samples is sufficiently large, it will surely make this trend is more obvious.' Section 2.3.1 (BLCA) repeats this pattern for PFS and DFS (Figs. 5-6), and Section 2.4.1 (EC) does the same for PFS (Fig. 7), each explicitly non-significant. No data cut-off, covariate adjustment, or hazard ratios are reported for any of these K-M curves. The conclusion then asserts that 'NSUN2 represents a critical prognostic marker for cancer.' The load-bearing problem is that non-significant trends are treated as if they corroborate the prognostic claim, and the missing statistical power is replaced by an unsubstantiated belief about sample size. A trend in the hypothesized direction with p > 0.05 is weak, inconclusive evidence; it can support the claim only if the direction is consistent across cohorts and a realistic power calculation shows that a modestly larger cohort would reach significance. Without such evidence, the authors' own data do not strengthen the central claim, and the conclusion overstates what these figures show.","agreement_with_reader":"agree"},"referee_report":{"model":"deepseek-v4-flash","summary":"This manuscript is a review-style paper claiming that the RNA methyltransferase NSUN2 is overexpressed in multiple cancers, promotes tumor progression through m5C modification, and is associated with poor patient prognosis. The authors synthesize published mechanistic and clinical studies for gastric, colorectal, lung, bladder, prostate, endometrial, and cervical cancer, and they present original TCGA-based Kaplan-Meier survival analyses (Figs. 4-7) as additional corroboration. The paper concludes that NSUN2 represents a critical prognostic marker and a promising therapeutic target. The review is broad and cites much of the relevant literature, but the authors' own survival analyses are explicitly non-significant and lack methodological detail, and the conclusions overstate the strength of this evidence.","tokens_in":14190,"tokens_out":3707,"duration_ms":38552,"significance":"If the central claim is correct, NSUN2 could serve as a clinically useful prognostic biomarker and a target for cancer therapy across multiple tumor types. The manuscript brings together a substantial body of literature and provides a useful overview of the mechanisms linking NSUN2, m5C modification, and cancer progression. However, the paper's own original contribution consists of four non-significant survival analyses that are presented as supporting evidence, and the text contains factual and citation errors. The prognostic and therapeutic claim is plausible on the basis of external studies, but the manuscript's own evidence base is fragile and the conclusion as written overstates what the presented data show.","major_comments":[{"comment":"The authors' own TCGA survival analyses are non-significant and are used to corroborate the prognostic claim. In Section 2.1.2 the text states, 'We believe that, when the number of samples is sufficiently large, it will surely make this trend is more obvious,' and similar statements appear in Sections 2.3.1 and 2.4.1. No data cut-off, covariate adjustment, hazard ratio, confidence interval, or software is reported for any of the four Kaplan-Meier analyses. A non-significant trend in the hypothesized direction is weak, inconclusive evidence, and the unsupported belief that a larger sample would 'surely' produce significance is not a substitute for a power analysis or for consistent significant results across cohorts. This is load-bearing because the Conclusion asserts that 'NSUN2 represents a critical prognostic marker for cancer.' Please either provide full statistical reporting with a realistic power calculation, or remove these analyses and explicitly temper the conclusion to reflect that the authors' own data do not provide statistically significant support.","section":"Sections 2.1.2, 2.3.1, 2.4.1; Figs. 4-7"},{"comment":"Reference [73] is malformed: it begins with a title fragment, contains the word 'cancernner,' and has an inconsistent citation format. More seriously, it is cited in Section 2.1.2 to support the statement that in colorectal cancer, patients with high NSUN2 expression had lower disease-free survival and that NSUN2 is an independent prognostic indicator for overall survival, but the reference title indicates the study is about NSUN2 in non-small cell lung cancer, not colorectal cancer. This citation mismatch undermines the specific prognostic claim for CRC. Please verify the intended source and correct the reference or the cited claim.","section":"Reference [73] and Section 2.1.2"},{"comment":"The Introduction and Conclusion state that the review covers ovarian cancer, and the Fig. 3 legend lists ovarian cancer and osteosarcoma, but the main text contains no section on ovarian cancer (and no section on osteosarcoma either). The cancers actually discussed are gastric, colorectal, lung, bladder, prostate, endometrial, and cervical. This inconsistency should be resolved by either adding the missing content or removing those mentions.","section":"Introduction, Section 3, Fig. 3 legend"}],"minor_comments":[{"comment":"The abbreviation 'NSCLC' is defined as 'Non-cancerous' and Section 2.2.1 states that 'approximately 85% of lung cancer cases are classified as non-cancerous (NSCLC).' NSCLC stands for non-small cell lung cancer, not non-cancerous; this is a factual error that should be corrected.","section":"Abbreviation list and Section 2.2.1"},{"comment":"The text refers to 'demethylases (“wipers”)'; the standard term is 'erasers' rather than 'wipers.'","section":"Introduction"},{"comment":"The phrase 'RNA double sequencing analysis' likely should be 'RNA sequencing analysis' or 'RNA bisulfite sequencing analysis'; please clarify.","section":"Section 2.1.1"},{"comment":"Several references are duplicated: [9] and [32] are the same article, [17] and [10] are the same article, and [33] duplicates [31]. Please deduplicate the bibliography.","section":"Reference list"},{"comment":"The Kaplan-Meier figure legends do not report the cut-off used to define high versus low NSUN2 expression, the statistical test, the p-value, or the number of events. Adding these details would improve reproducibility and interpretation.","section":"Figures 4-7"},{"comment":"The abbreviation 'USUN' is listed but not used or defined in the text; please remove or explain it.","section":"Abbreviation list"},{"comment":"The phrase 'm5C modification is a type of RNA methylation modification' is imprecise because m5C also occurs in DNA; the text later acknowledges this, but the abstract should be tightened.","section":"Abstract and Section 1"}],"recommendation":"major_revision","confidential_remarks":"The paper is essentially a literature review with a small amount of original survival analysis. The non-significant results and missing methodological details in the original analyses, together with the citation error and factual mislabeling of NSCLC, make the current version unsuitable for publication without substantial revision. The central hypothesis is not implausible and the review covers a useful topic, but the manuscript needs to either remove the authors' own non-significant analyses or report them rigorously and adjust the strength of the conclusions accordingly."},"author_rebuttal":null,"desk_editor":{"model":"deepseek-v4-flash","letter":"I agree with the reader's take, and the stress-test note holds up. This is a narrative review, not a research preprint. Its central claim — that NSUN2 is overexpressed across many tumor types and that high expression tracks with poor prognosis — is already the field's working consensus, and the paper cites the right primary papers to support it. What the authors add themselves is four TCGA Kaplan-Meier analyses (CRC PFS, BLCA PFS/DFS, EC PFS), and every one of them is reported as not statistically significant.\n\nThe notable thing is that the authors do not hide this. They state clearly in Sections 2.1.2, 2.3.1, and 2.4.1 that the results were not statistically significant. That transparency earns some credit. The problem is what they do next: instead of treating the non-significance as a non-result, they assert that a larger sample \"will surely\" make the trend obvious. That is a belief, not an analysis, and the stress-test is right that it is load-bearing. The conclusion's \"critical prognostic marker for cancer\" phrasing depends on those figures more than they can carry. The cited literature (refs 27, 44, 60, 64, 74, 75) does independently support the prognostic association, so the central claim survives on borrowed strength — but the paper's own contribution adds none.\n\nWhat the review does well: the per-cancer organization is clean, the mechanism sections (m5C-dependent regulation of target mRNAs like p57, SKIL, LRRC8A, KRT13) track the cited papers accurately, and the 2021-2025 reference list is current. A reader wanting a compact map of the NSUN2/m5C cancer literature would find this useful.\n\nSoft spots, in proportion. The TCGA analyses have no methods at all — no cut-off, no covariate adjustment, no hazard ratios, no software versions. If these figures stay, the authors need to describe the analysis or drop the figures. \"NSCLC: Non-cancerous\" in the abbreviation list and in Section 2.2.1 is a factual error that must be fixed. Reference [73] is malformed (\"cancernner\", Clin Transl Med 2025) and appears to be a mangled duplicate of the NSCLC paper already cited as [54]. The introduction and conclusion mention ovarian cancer, but there is no ovarian section in the text.\n\nNovelty is genuinely low — this is a compilation of existing findings — but that is the nature of a review, not a flaw in execution. For a specialist, there is nothing new here; for someone new to the area, it is an acceptable starting point.\n\nRecommendation: have a competent referee review it, but the bar for acceptance should be that the authors either delete Figs 4-7 or report them properly with a hedged interpretation, fix the NSCLC error and the reference, and soften the conclusion to match what the cited primary literature actually shows. My own verdict would be major revision at best.","headline":"A serviceable review that accurately summarizes the NSUN2 literature, but its one original element (non-significant TCGA survival curves) is presented as corroboration on the strength of a belief about sample size, not evidence.","tokens_in":14819,"tokens_out":5756,"would_cite":false,"duration_ms":49939,"reading_group":"maybe","serious_thinker":"yes","would_accept_peer_review":true},"rs_alignment":null,"lean_confirmation":null,"pith_extraction":{"msc":[],"pacs":[],"model":"deepseek-v4-flash","headline":"This review argues that NSUN2, the main m5C RNA methyltransferase, is overexpressed across many cancers, tracks with poor survival, and should be tested as a prognostic marker and therapeutic target.","keywords":["NSUN2","m5C modification","RNA methylation","cancer prognosis","therapeutic target","biomarker","TCGA survival analysis","oncogene"],"falsifier":"A well-powered prospective study with multivariable adjustment for tumor stage, grade, age, and treatment that found no independent association between NSUN2 expression and overall or progression-free survival in these cancer types would refute the prognostic claim; a clinical trial in which NSUN2 inhibition changed neither tumor growth nor patient survival would refute the therapeutic claim.","tokens_in":13750,"feed_emoji":"🧬","tokens_out":6338,"duration_ms":59756,"temperature":0.7,"pith_summary":"This review makes the case that NSUN2, the principal enzyme that writes m5C marks on RNA, is a common feature of cancer and a clinically useful one. It argues that NSUN2 is overexpressed in gastric, colorectal, lung, bladder, prostate, endometrial, and cervical cancers, that high expression accompanies larger tumors and more advanced stages, and that patients with high NSUN2 tend to have worse overall, progression-free, or disease-free survival. The paper also describes a consistent mechanism: NSUN2 deposits m5C on specific messenger RNAs, stabilizing or increasing their translation, and in that way drives proliferation, migration, and invasion. The authors' own survival analyses from public databases show the expected trend but are not statistically significant, a limitation they attribute to small sample size. The payoff, if the pattern holds, is that NSUN2 expression could serve as a prognostic indicator and NSUN2 itself as a target for therapy across multiple cancer types.","feed_headline":"NSUN2 enzyme links many cancers to worse outcomes","feed_subtitle":"Review of eight cancer types argues NSUN2 drives tumors via m5C methylation and could guide therapy.","key_machinery":"The central object is NSUN2, an NOP2/Sun-domain RNA methyltransferase that catalyzes 5-methylcytosine (m5C) modification of RNA by transferring methyl groups to cytosine residues. The argument turns on the writer–reader system for m5C: NSUN2 deposits the mark, proteins such as ALYREF read it, and the mark alters messenger RNA stability, export, or translation efficiency. The paper uses enzyme-dead mutant constructs, RNA bisulfite sequencing, knockdown and overexpression cell lines, mouse xenograft models, and survival analyses of public tumor cohorts to connect NSUN2's enzymatic activity to the expression of downstream targets and, ultimately, to tumor progression and patient outcome.","core_discovery":"On its own terms, the paper claims that NSUN2 represents a critical prognostic marker for cancer and a promising therapeutic target. The evidence assembled is that NSUN2 is consistently upregulated in tumor tissue relative to normal tissue across at least seven cancer types; that its expression correlates with tumor size, grade, and TNM stage in several of them; and that high expression is associated with shorter survival in Kaplan–Meier and Cox analyses, with the review's own TCGA and GEO analyses showing the same direction. Mechanistically, the paper argues the oncogenic effect is m5C-dependent: wild-type NSUN2, but not an enzyme-dead mutant, restores proliferation and metastasis in NSUN2-deficient cells, and knockdown sharply reduces m5C peaks on mRNA. The claimed consequence is that reducing NSUN2 expression or blocking its methyltransferase activity could improve patient prognosis.","pith_inferences":["The authors leave implicit that their non-significant survival analyses mean the prognostic claim is not yet definitive; a reader should treat it as a testable hypothesis rather than an established clinical fact.","A natural extension the paper does not develop is to measure m5C levels or NSUN2's target mRNAs directly in patient samples, which could show whether expression level alone or the specific m5C target profile predicts survival better.","If NSUN2 is validated as a driver, an important open question is whether its role is consistent across cancer types or context-dependent, since some of the cited associations may reflect passenger effects of broader epigenetic dysregulation."],"forward_implications":["If the pattern holds, NSUN2 expression could be added to clinical staging to identify cancer patients at higher risk of progression.","Blocking NSUN2's methyltransferase activity, or disrupting the m5C marks it writes, could slow tumor growth across multiple cancer types.","Because the oncogenic effect appears to require m5C, drugs targeting m5C writers or readers may be more broadly useful than drugs aimed at any single downstream gene.","The consistent survival association suggests NSUN2 could be incorporated into prognostic panels and used to stratify patients in future trials."],"supporting_citations":[{"why":"Supplies the gastric cancer evidence that NSUN2 promotes proliferation and metastasis in an m5C-dependent manner and links high NSUN2 to worse overall survival.","marker":"[27]"},{"why":"Shows NSUN2 promotes gastric cancer cell proliferation by repressing p57Kip2 in an m5C-dependent manner, supporting the pro-oncogenic mechanism.","marker":"[38]"},{"why":"Documents NSUN2 overexpression in colorectal cancer and shows knockdown suppresses proliferation and invasiveness.","marker":"[43]"},{"why":"Provides colorectal cancer in vivo xenograft and clinicopathological data linking high NSUN2 with reduced overall survival.","marker":"[44]"},{"why":"Establishes NSUN2 upregulation in non-small cell lung cancer and its correlation with tumor stage and size, with functional knockdown data.","marker":"[54]"},{"why":"Reports bladder cancer data associating high NSUN2 expression with reduced overall survival and negative correlation with survival duration.","marker":"[60]"},{"why":"Shows NSUN2 overexpression in cervical cancer promotes proliferation, migration, and invasion and regulates LRRC8A through m5C modification.","marker":"[63]"},{"why":"Provides prostate cancer evidence that NSUN2 promotes progression and that high expression is associated with lower PFS, DFS, and OS.","marker":"[64]"},{"why":"Documents NSUN2 upregulation in endometrial cancer, m5C-dependent proliferation effects, and correlation with FIGO stage and histological grade.","marker":"[71]"},{"why":"Provides gynecologic cancer survival analysis showing cervical cancer patients with high NSUN2 have worse overall survival.","marker":"[75]"}],"fun_headline_variants":["Blocking NSUN2's m5C activity could treat multiple cancers","NSUN2 drives cancer via RNA methylation; new target emerges","NSUN2's m5C marks predict cancer survival and therapy response","m5C writer NSUN2: prognostic marker and therapeutic target in cancer","NSUN2 enzyme: a common cancer lever with prognostic and therapeutic promise"],"cache_read_input_tokens":3200,"weakest_assumption_plain":"The load-bearing premise is that the survival trends the authors see in their own analyses, which they acknowledge are not statistically significant, would become clear and meaningful with larger samples, and that high NSUN2 expression is a cause of poor prognosis rather than a coincidental correlate.","fun_headline_variants_meta":{"raw":{"variants":["Blocking NSUN2's m5C activity could treat multiple cancers","NSUN2 drives cancer via RNA methylation; new target emerges","NSUN2's m5C marks predict cancer survival and therapy response","m5C writer NSUN2: prognostic marker and therapeutic target in cancer","NSUN2 enzyme: a common cancer lever with prognostic and therapeutic promise"]},"model":"deepseek-v4-flash","effort":"low","cost_usd":0.000823,"raw_usage":{"total_tokens":3549,"prompt_tokens":843,"completion_tokens":2706,"prompt_tokens_details":{"cached_tokens":384},"prompt_cache_hit_tokens":384,"prompt_cache_miss_tokens":459,"completion_tokens_details":{"reasoning_tokens":2611}},"tokens_in":459,"tokens_out":2706,"duration_ms":19683,"temperature":1.0,"reasoning_tokens":2611,"cache_read_input_tokens":384,"cache_creation_input_tokens":0},"cache_creation_input_tokens":0},"created_at":"2026-08-07T05:51:34.139298+00:00","model_set":{"reader":"deepseek-v4-flash"},"falsifier":"A well-powered prospective study with multivariable adjustment for tumor stage, grade, age, and treatment that found no independent association between NSUN2 expression and overall or progression-free survival in these cancer types would refute the prognostic claim; a clinical trial in which NSUN2 inhibition changed neither tumor growth nor patient survival would refute the therapeutic claim.","supporting_citations":[{"cited_title":"NSUN2 modified by SUMO- 2/3 promotes gastric cancer progression and regulates mRNA m5C methylation","cited_arxiv_id":null,"evidence_quote":"Supplies the gastric cancer evidence that NSUN2 promotes proliferation and metastasis in an m5C-dependent manner and links high NSUN2 to worse overall survival."},{"cited_title":null,"cited_arxiv_id":null,"evidence_quote":"Shows NSUN2 promotes gastric cancer cell proliferation by repressing p57Kip2 in an m5C-dependent manner, supporting the pro-oncogenic mechanism."},{"cited_title":"Metabolic Recoding of NSUN2-Mediated m5C Modification Promotes the Progression of Colorectal Cancer via the NSUN2/YBX1/m5C -ENO1 Positive Feedback Loop","cited_arxiv_id":null,"evidence_quote":"Documents NSUN2 overexpression in colorectal cancer and shows knockdown suppresses proliferation and invasiveness."},{"cited_title":"NSUN2 promotes colorectal cancer progression by enhancing SKIL mRNA stabilization","cited_arxiv_id":null,"evidence_quote":"Provides colorectal cancer in vivo xenograft and clinicopathological data linking high NSUN2 with reduced overall survival."},{"cited_title":"5 -Methylcytosine transferase NSUN2 drives NRF2 -mediated ferroptosis resistance in non - small cell lung cancer","cited_arxiv_id":null,"evidence_quote":"Establishes NSUN2 upregulation in non-small cell lung cancer and its correlation with tumor stage and size, with functional knockdown data."},{"cited_title":"NSUN2 -mediated R-loop stabilization as a key driver of bladder cancer progression and cisplatin sensitivity","cited_arxiv_id":null,"evidence_quote":"Reports bladder cancer data associating high NSUN2 expression with reduced overall survival and negative correlation with survival duration."},{"cited_title":"Upregulation of LRRC8A by m5C modification -mediated mRNA stability suppresses apoptosis and facilitates tumorigenesis in cervical cancer","cited_arxiv_id":null,"evidence_quote":"Shows NSUN2 overexpression in cervical cancer promotes proliferation, migration, and invasion and regulates LRRC8A through m5C modification."},{"cited_title":"Positive epigenetic regulation loop between AR and NSUN2 promotes prostate cancer progression","cited_arxiv_id":null,"evidence_quote":"Provides prostate cancer evidence that NSUN2 promotes progression and that high expression is associated with lower PFS, DFS, and OS."},{"cited_title":"RNA 5 -Methylcytosine regulators are associated with cell adhesion and predict prognosis of endometrial cancer","cited_arxiv_id":null,"evidence_quote":"Documents NSUN2 upregulation in endometrial cancer, m5C-dependent proliferation effects, and correlation with FIGO stage and histological grade."},{"cited_title":"Distinct Roles of m5C RNA Methyltransferase NSUN2 in Major Gynecologic Cancers","cited_arxiv_id":null,"evidence_quote":"Provides gynecologic cancer survival analysis showing cervical cancer patients with high NSUN2 have worse overall survival."}],"review_version":1}